W Vaudry1, R Stirling2. 1. NACI Influenza Working Group Chair, University of Alberta, Edmonton, AB. 2. Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Abstract
BACKGROUND: Influenza is a respiratory infection caused primarily by influenza A and B viruses. Vaccination is the most effective way to prevent influenza and its complications. The National Advisory Committee on Immunization (NACI) provides recommendations regarding seasonal influenza vaccines annually to the Public Health Agency of Canada (PHAC). OBJECTIVE: To summarize the NACI recommendations regarding the use of seasonal influenza vaccines for the 2017-2018 influenza season. METHODS: Annual influenza vaccine recommendations are developed by NACI's Influenza Working Group for consideration and approval by NACI, based on NACI's evidence-based process for developing recommendations. The recommendations include a consideration of the burden of influenza illness and the target populations for vaccination; efficacy and effectiveness, immunogenicity and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. These recommendations are published annually on the Agency's website in the NACI Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine (the Statement). RESULTS: The annual statement has been updated for the 2017-2018 influenza season to incorporate recommendations for the use of live attenuated influenza vaccine (LAIV) that were contained in two addenda published after the 2016-2017 statement. These recommendations were 1) that egg-allergic individuals may be vaccinated against influenza using the low ovalbumin-containing LAIV licensed for use in Canada and 2) to continue to recommend the use of LAIV in children and adolescents 2-17 years of age, but to remove the preferential recommendation for its use. CONCLUSION: NACI continues to recommend annual influenza vaccination for all individuals aged six months and older, with particular focus on people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and others as indicated.
BACKGROUND: Influenza is a respiratory infection caused primarily by influenza A and B viruses. Vaccination is the most effective way to prevent influenza and its complications. The National Advisory Committee on Immunization (NACI) provides recommendations regarding seasonal influenza vaccines annually to the Public Health Agency of Canada (PHAC). OBJECTIVE: To summarize the NACI recommendations regarding the use of seasonal influenza vaccines for the 2017-2018 influenza season. METHODS: Annual influenza vaccine recommendations are developed by NACI's Influenza Working Group for consideration and approval by NACI, based on NACI's evidence-based process for developing recommendations. The recommendations include a consideration of the burden of influenza illness and the target populations for vaccination; efficacy and effectiveness, immunogenicity and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. These recommendations are published annually on the Agency's website in the NACI Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine (the Statement). RESULTS: The annual statement has been updated for the 2017-2018 influenza season to incorporate recommendations for the use of live attenuated influenza vaccine (LAIV) that were contained in two addenda published after the 2016-2017 statement. These recommendations were 1) that egg-allergic individuals may be vaccinated against influenza using the low ovalbumin-containing LAIV licensed for use in Canada and 2) to continue to recommend the use of LAIV in children and adolescents 2-17 years of age, but to remove the preferential recommendation for its use. CONCLUSION: NACI continues to recommend annual influenza vaccination for all individuals aged six months and older, with particular focus on people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and others as indicated.
Authors: Anne Des Roches; Kathryn Samaan; François Graham; Jonathan Lacombe-Barrios; Jean Paradis; Louis Paradis; Gaston De Serres Journal: J Allergy Clin Immunol Pract Date: 2014-10-03
Authors: R G Pebody; H K Green; N Andrews; H Zhao; N Boddington; Z Bawa; H Durnall; N Singh; A Sunderland; L Letley; J Ellis; A J Elliot; M Donati; G E Smith; S de Lusignan; M Zambon Journal: Euro Surveill Date: 2014-06-05
Authors: Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Jonathan Gubbay; Kevin Fonseca; Hugues Charest; Mel Krajden; Martin Petric; Salaheddin M Mahmud; Paul Van Caeseele; Nathalie Bastien; Alireza Eshaghi; Yan Li Journal: J Infect Dis Date: 2015-03-17 Impact factor: 5.226
Authors: Danuta M Skowronski; Travis S Hottes; Mei Chong; Gaston De Serres; David W Scheifele; Brian J Ward; Scott A Halperin; Naveed Z Janjua; Tracy Chan; Suzana Sabaiduc; Martin Petric Journal: Pediatrics Date: 2011-07-18 Impact factor: 7.124
Authors: Jeffrey C Kwong; Jennifer A Pereira; Susan Quach; Rosana Pellizzari; Edwina Dusome; Margaret L Russell; Jemila S Hamid; Yael Feinberg; Anne-Luise Winter; Jonathan B Gubbay; Brittany Sirtonski; Deanna Moher; Doug Sider; Michael Finkelstein; Mark Loeb Journal: Vaccine Date: 2015-07-29 Impact factor: 3.641
Authors: Herve Caspard; Manjusha Gaglani; Lydia Clipper; Edward A Belongia; Huong Q McLean; Marie R Griffin; H Keipp Talbot; Katherine A Poehling; Timothy R Peters; Naomi Veney; Christopher S Ambrose Journal: Vaccine Date: 2015-11-14 Impact factor: 3.641
Authors: Sarah A Buchan; Stephanie Booth; Allison N Scott; Kimberley A Simmonds; Lawrence W Svenson; Steven J Drews; Margaret L Russell; Natasha S Crowcroft; Mark Loeb; Bryna F Warshawsky; Jeffrey C Kwong Journal: JAMA Pediatr Date: 2018-09-04 Impact factor: 16.193
Authors: David Jackson; Max Pitcher; Chris Hudson; Nick Andrews; Jo Southern; Joanna Ellis; Katja Höschler; Richard Pebody; Paul J Turner; Elizabeth Miller; Maria Zambon Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079